TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22735869

Group type: EXPERIMENTAL
Intervention: Felypressin added to prilocaine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Prilocaine without felypressin
Number of subjects: 71
Study: 21203706

Group type: EXPERIMENTAL
Intervention: Resin composite restorations (Excite/Tetric Ceram)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RMGIC) (Vitremer/3M)
Number of subjects: 30
Study: 18055943

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 57
Study: 16350383

Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin-bonded circuits
Number of subjects: 40
Study: 12115160

Group type: EXPERIMENTAL
Intervention: Psychological interventions (e.g., relaxation, biofeedback, cognitive‐behavioral therapy)
Number of subjects: 25
Study: 9857535

Group type: EXPERIMENTAL
Intervention: Dexamethasone (250 mg), Promethazine (300 mg), Dextran 70 (500 ml intraperitoneally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (10 women)
Number of subjects: 30
Study: 8589875

Group type: EXPERIMENTAL
Intervention: Left-sided approach
Number of subjects: 345

Group type: COMPARATOR
Intervention: Right-sided approach
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Left-sided approach with submuscular or subcutaneous patch
Number of subjects: 345

Group type: COMPARATOR
Intervention: Right-sided approach with submuscular or subcutaneous patch
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Left-sided approach without submuscular or subcutaneous patch
Number of subjects: 345

Group type: COMPARATOR
Intervention: Right-sided approach without submuscular or subcutaneous patch
Number of subjects: 345
Study: 2112500

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 371803

Group type: EXPERIMENTAL
Intervention: Maytansine
Number of subjects: 54
Study: 31302000

Group type: EXPERIMENTAL
Intervention: Aspiration Therapy (AT) plus Lifestyle Therapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Lifestyle Therapy
Number of subjects: 171
Study: 29085538

Group type: EXPERIMENTAL
Intervention: Heated gel (102.0° F)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Room-temperature gel (82.3° F)
Number of subjects: 124
Study: 25982449

Group type: EXPERIMENTAL
Intervention: Ligaclips (Group A)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS) (Group B)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: LigaSure (LS) (Group C)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Comparison of Ligaclips vs LigaSure
Number of subjects: 420

Group type: COMPARATOR
Intervention: Comparison of HS vs Ligaclips
Number of subjects: 420

Group type: COMPARATOR
Intervention: Comparison of HS vs LigaSure
Number of subjects: 420
Study: 23607594

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus peginterferon alfa-2a and ribavirin for 12 weeks
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 826

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a plus ribavirin for 24 weeks
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 826

Group type: COMPARATOR
Intervention: Peginterferon
Number of subjects: 826
Study: 21762229

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 2 mg inhalation suspension
Number of subjects: 180

Group type: COMPARATOR
Intervention: Normal sterile saline (NSS) placebo
Number of subjects: 180
Study: 19372573

Group type: EXPERIMENTAL
Intervention: Wisconsin Predicting Patient's Relapse (WI‐PREPARE) measure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 0
Study: 16293676

Group type: EXPERIMENTAL
Intervention: FAMTX (5-fluorouracil + adriamycin + methotrexate with leucovorin rescue)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: FEMTX (5-fluorouracil + epirubicin + methotrexate with leucovorin rescue)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 397
Study: 12858356

Group type: EXPERIMENTAL
Intervention: Previously untreated prostate cancer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HRPC
Number of subjects: 30

Group type: COMPARATOR
Intervention: BPH
Number of subjects: 30
Study: 10928252

Group type: EXPERIMENTAL
Intervention: Mechanical autotransfusion devices
Number of subjects: 100
Study: 8956674

Group type: EXPERIMENTAL
Intervention: Clozapine (mean final dose 176 ± 149 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Haloperidol (mean final dose 16 ± 8 mg/d)
Number of subjects: 21
Study: 1285568

Group type: EXPERIMENTAL
Intervention: L-648,051 (6 mg, four times daily for 7 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-648,051 (6 mg, inhaled before antigen challenge)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3516295

Group type: EXPERIMENTAL
Intervention: emepronium carrageenate (Cetiprin novum)
Number of subjects: 72
Study: 28986963

Group type: EXPERIMENTAL
Intervention: Pure Rush
Number of subjects: 281

Group type: COMPARATOR
Intervention: Active control lesson
Number of subjects: 281
Study: 27383395

Group type: EXPERIMENTAL
Intervention: Discrimination maps for AD versus SCD
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Discrimination maps for AD versus MCI
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Discrimination maps for MCI versus SCD
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Discrimination maps for MCI converted to AD versus SCD
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Discrimination maps for MCI converted to AD versus stable MCI
Number of subjects: 286
Study: 25571980

Group type: EXPERIMENTAL
Intervention: Plasma iGFR
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Urinary iGFR
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Plasma iGFR and Urinary iGFR
Number of subjects: 147
Study: 22849787

Group type: EXPERIMENTAL
Intervention: Automated text messaging (SMS) system providing daily queries about prescription pickup and dosage taken with educational feedback
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual printed discharge instructions
Number of subjects: 200
Study: 20537396

Group type: EXPERIMENTAL
Intervention: Asenapine (5 or 10mg BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20mg QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/Asenapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study: 18197974

Group type: EXPERIMENTAL
Intervention: Lactobacilli treatment (109 freeze-dried lactobacilli for 10 days during 3 menstrual cycles)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment (identical placebo capsules for 10 days during 3 menstrual cycles)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lactobacilli treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 15924533

Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Expectant management only
Number of subjects: 34
Study: 14764424

Group type: EXPERIMENTAL
Intervention: Plant sterol-fortified orange juice (sterol OJ) (2g/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo orange juice (placebo OJ)
Number of subjects: 72
Study: 11513221

Group type: EXPERIMENTAL
Intervention: Hierarchical linear modeling
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: Analysis of variance
Number of subjects: 2746
Study: 9216851

Group type: EXPERIMENTAL
Intervention: PVB chemotherapy (cisplatin, vinblastine, bleomycin)
Number of subjects: 148

Group type: COMPARATOR
Intervention: CAP chemotherapy (cyclophosphamide, aclacinomycin, cisplatin)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: PVB chemotherapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: CAP chemotherapy
Number of subjects: 148
Study: 8127221

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 121008

Group type: EXPERIMENTAL
Intervention: BCG + 5 x 10(7) killed Mycobacterium leprae
Number of subjects: 121008

Group type: EXPERIMENTAL
Intervention: BCG + 6 x 10(8) killed M. leprae
Number of subjects: 121008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121008

Group type: EXPERIMENTAL
Intervention: BCG (from mid-1987 onwards)
Number of subjects: 121008
Study: 3492975

Group type: EXPERIMENTAL
Intervention: Diltiazem at 100 micrograms/kg (D-100)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Diltiazem (various doses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Diltiazem at 50 micrograms/kg (D-50) and 100 micrograms/kg (D-100)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 29879968

Group type: EXPERIMENTAL
Intervention: 18-week supervised exercise program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study: 27788313

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Therapy for Insomnia (CTRL)
Number of subjects: 150
Study: 24999158

Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHW's) intervention with monthly visits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 22890910

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TBI cases
Number of subjects: 84

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TBI patients <1 year
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TBI patients >1 year
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Abusive head trauma (AHT) cases
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Non-abusive TBI cases
Number of subjects: 84
Study: 20411218

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (8-week supervised rehabilitation programme)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study: 18597921

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine devices (LNG-IUD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRHa)
Number of subjects: 60
Study: 16642920

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administered at 20 ng/kg/min from just after the induction of anesthesia to the end of surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no PGE1 treatment)
Number of subjects: 24
Study: 14714362

Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western Medicine (ICWM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Western Medicine (Control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups (ICWM and Control)
Number of subjects: 63
Study: 10813120

Group type: EXPERIMENTAL
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 77
Study: 10323118

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.6 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral chloral hydrate (50 mg/kg)
Number of subjects: 23
Study: 1279288

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 4008807

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (24 mg per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (doubled dose from days 22 to 24)
Number of subjects: 10
Study: 29459468

Group type: COMPARATOR
Intervention: Healthy lifestyle score based on a recently developed algorithm
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Genetic predispositions (mutations causing monogenic hypocholesterolemia)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Genetic predispositions (high-weighted genetic risk score)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia mutations
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High-weighted genetic risk score
Number of subjects: 240

Group type: COMPARATOR
Intervention: Lifestyle assessment
Number of subjects: 240
Study: 27574913

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 10
Study: 25129967

Group type: COMPARATOR
Intervention: Modified Epley maneuver alone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Self-treatment combined with modified Epley maneuver
Number of subjects: 147

Group type: COMPARATOR
Intervention: Hand repositioning in modified Epley-alone group
Number of subjects: 147

Group type: COMPARATOR
Intervention: Chair-assisted repositioning in modified Epley-alone group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Hand repositioning in self-treatment group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Chair-assisted repositioning in self-treatment group
Number of subjects: 147

Group type: COMPARATOR
Intervention: Modified Epley-alone group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Self-treatment group
Number of subjects: 147
Study: 22526448

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 372

Group type: COMPARATOR
Intervention: Non-cryoanalgesia
Number of subjects: 372
Study: 19889241

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC) (5 mg caffeine/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Decaffeinated coffee (DC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 10
Study: 18620591

Group type: COMPARATOR
Intervention: Ringer solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HES 130‐0.4 solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Number of subjects: 140
Study: 16134046

Group type: EXPERIMENTAL
Intervention: Advocacy services (short-term, free)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No advocacy services (control group)
Number of subjects: 124
Study: 12462286

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution BID
Number of subjects: 185

Group type: COMPARATOR
Intervention: Cromolyn 2% ophthalmic solution QID
Number of subjects: 185
Study: 10730526

Group type: EXPERIMENTAL
Intervention: Gentamicin 4.5 mg/kg/d once daily (OD group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gentamicin 4.5 mg/kg/d in three divided doses (TID group)
Number of subjects: 49
Study: 7670450

Group type: EXPERIMENTAL
Intervention: High Carbohydrate Diet (HCD) - 4.5 +/‐ 0.5 g CHO.kg‐1.d‐1 for 3 days followed by 8.2 +/‐ 0.4 g CHO.kg‐1.d‐1 for 3 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mixed Diet (MD) - 4.0 +/‐ 0.5 g.kg‐1.d‐1 of carbohydrate for 6 days
Number of subjects: 8
Study: 2209318

Group type: EXPERIMENTAL
Intervention: Intensive educational approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 70
Study: 7389388

Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg 8-hourly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ampicillin 250 mg 6-hourly
Number of subjects: 50
Study: 31841363

Group type: COMPARATOR
Intervention: Standard-Dose Radiation (60 Gy) with concurrent chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Dose Radiation (74 Gy) with concurrent chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study: 31487657

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 490
Study: 27348462

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy via computer teleconferencing
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy via iPhone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 27
Study: 26418677

Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 575
Study: 23404724

Group type: EXPERIMENTAL
Intervention: PILI Lifestyle Program (PLP; n = 49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Behavior Weight Loss Program (SBP; n = 51)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Initial weight loss in the first 3-months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chuukese ethnicity
Number of subjects: 100
Study: 21539729

Group type: EXPERIMENTAL
Intervention: C1,2C at baseline
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Change in C2C
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Change in C1,2C
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Sum of the standardized changes in C2C + C1,2C scores
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Change in CPII
Number of subjects: 133
Study: 19121466

Group type: EXPERIMENTAL
Intervention: Kinesiotherapy and active muscular stretching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Global Myofascial Physiotherapy (Mézières method)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 18057480

Group type: EXPERIMENTAL
Intervention: Cefpodoxime Proxetil (CP) 16 mg/kg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefixime (CF) 20 mg/kg/day
Number of subjects: 40
Study: 15628812

Group type: EXPERIMENTAL
Intervention: Insulin glargine (Lantus)
Number of subjects: 196

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 196
Study: 11581543

Group type: EXPERIMENTAL
Intervention: 3-month exercise program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 18-month exercise program (long-term group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 18-month exercise program (short-term group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3-month to 18-month cognitive performance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall exercise intervention
Number of subjects: 100
Study: 11006365

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (30 microg weekly intramuscular injections)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo (weekly injections)
Number of subjects: 383
Study: 8875379

Group type: EXPERIMENTAL
Intervention: Dried garlic tablets (standardised to 1.3% allicin) at a dosage of 300 mg three times daily
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Garlic (from meta-analysis)
Number of subjects: 115
Study: 2049420

Group type: EXPERIMENTAL
Intervention: Vancomycin 25 mgm/L
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cefazolin 50 mgm/L
Number of subjects: 131
Study: 6839757

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oestrogen-progestogen combination
Number of subjects: 101
Study: 30879126

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3% saline
Number of subjects: 30
Study: 30499227

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Treatment (GCBT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Group Present-Centered Treatment (GPCT)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: GCBT and GPCT
Number of subjects: 198
Study: 26768924

Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combined propofol and sevoflurane (Group PS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 126
Study: 23917853

Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation
Number of subjects: 68
Study: 22927775

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg.kg(‐1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Propofol-lidocaine mixture (20 mg lidocaine with 180 mg 1% propofol)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Normal saline placebo (Control group)
Number of subjects: 119
Study: 20692774

Group type: EXPERIMENTAL
Intervention: Ambulation until 6cm of cervical dilation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Confined to bed in dorsal or lateral recumbence
Number of subjects: 200
Study: 18971479

Group type: EXPERIMENTAL
Intervention: Donepezil (acetylcholinesterase inhibitor)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 28
Study: 16420891

Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 54

Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 54
Study: 11777514

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg per hour
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol 1.0 mg/kg per hour
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg per hour
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10374081

Group type: EXPERIMENTAL
Intervention: Masked quality assessment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Unmasked quality assessment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low-quality trials
Number of subjects: 127

Group type: COMPARATOR
Intervention: Inadequate allocation concealment
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Low quality trials only
Number of subjects: 127

Group type: COMPARATOR
Intervention: High quality trials only
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All trial scores as quality weights
Number of subjects: 127
Study: 7627338

Group type: EXPERIMENTAL
Intervention: Intramuscular hMG at a daily dose of 150 IU in combination with buserelin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pulsatile intravenous hMG at a daily dose of 112.5 IU in combination with buserelin
Number of subjects: 14
Study: 2039326

Group type: EXPERIMENTAL
Intervention: One-dose cefazolin
Number of subjects: 208

Group type: COMPARATOR
Intervention: Six-dose cefazolin
Number of subjects: 208
Study: 31335805

Group type: EXPERIMENTAL
Intervention: raltegravir and lamivudine
Number of subjects: 75

Group type: COMPARATOR
Intervention: control
Number of subjects: 75